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The HIV auxiliary protein Vpr potently blocks the cell
cycle at the G2/M transition. Here, we show that
G2/M arrest results from untimely activation of the
structure-specific endonuclease (SSE) regulator
SLX4 complex (SLX4com) by Vpr, a process that
requires VPRBP-DDB1-CUL4 E3-ligase complex.
Direct interaction of Vpr with SLX4 induced the
recruitment of VPRBP and kinase-active PLK1,
enhancing the cleavage of DNA by SLX4-associated
MUS81-EME1 endonucleases. G2/M arrest-deficient
Vpr alleles failed to interact with SLX4 or to induce
recruitment of MUS81 and PLK1. Furthermore,
knockdown of SLX4, MUS81, or EME1 inhibited Vpr-
induced G2/M arrest. In addition, we show that the
SLX4com is involved in suppressing spontaneous
and HIV-1-mediated induction of type 1 interferon
and establishment of antiviral responses. Thus, our
worknotonly reveals the identityof thecellular factors
required for Vpr-mediated G2/M arrest but also iden-
tifies the SLX4com as a regulator of innate immunity.
INTRODUCTION
Many viruses, including HIV-1, perturb the progression through
the host cell cycle. This is achieved through subversion of the
boundaries between the DNA replication step (S), segregation
of sister chromatids (mitosis), and the gap phases (G1 and G2)
(Davy and Doorbar, 2007). Manipulation of the host cell cycle
by HIV-1 is achieved through the highly conserved 96 amino
acid Vpr protein that causes a potent cell-cycle arrest at the
G2 to mitosis transition (G2/M) in most cycling eukaryotic cells
(Di Marzio et al., 1995; He et al., 1995; Jowett et al., 1995; Re
et al., 1995; Rogel et al., 1995). G2/M arrest by Vpr has been
proposed to rely on Vpr-induced activation of the DNA damage
surveillance proteins ataxia-telangiectasia-mutated kinase
(ATM) and ATM and Rad3-related kinase (ATR) that detect134 Cell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc.DNA lesions and trigger downstream signaling cascades (Poon
et al., 1997; Roshal et al., 2003). Activation of ATM and ATR
may cause cell-cycle arrest, which, in the absence of HIV-1
infection, allows time for repair. Importantly, although Vpr
expression results in formation of breast cancer susceptibility
protein 1 (BRCA1) and gH2ax foci (Zimmerman et al., 2004), it re-
mains unclear whether Vpr induces double-strand breaks (DSB)
(Lai et al., 2005; Tachiwana et al., 2006) andwhether this damage
would be the trigger for cell-cycle arrest. A proposed scenario is
that Vpr activates the G2/M checkpoint through a replication
stress-dependent pathway (Li et al., 2010). Cellular partners of
Vpr that may contribute to G2/M arrest have been proposed,
yet no consensus has been reached apart from the absolute
requirement for the VPRBP-DDB1-CUL4 E3-ligase complex
(Belzile et al., 2007; DeHart et al., 2007; Hrecka et al., 2007; Le
Rouzic et al., 2007; Tan et al., 2007; Wen et al., 2007).
Homologous recombination (HR) is a crucial repair pathway in
mammalian cells, employed to repair DSB and collapsed replica-
tion forks. HR allows accurate repair using the sister chromatid
as a template and leads to the formation of four-way DNA struc-
tures, Holliday junctions (HJ), that must be removed prior to
chromosome segregation. In somatic cells, the favored pathway
to remove HJ relies on Bloom-related helicases that dissolve HJ
in a nonendonucleolytic fashion that prevents sister chromatid
exchanges (SCE) (Wu and Hickson, 2003). Failure to dissolve
HJ may be rescued by the resolution pathway that relies
on structure-specific endonuclease (SSE). In human cells,
MUS81-EME1, SLX1-SLX4, and GEN1 have been involved in
this process (Schwartz and Heyer, 2011). Though these proteins
display different activities in vitro, in vivo SLX4 acts as a central
scaffold that, in addition to interacting with SLX1, also recruits
MUS81-EME1 and ERCC1-ERCC4XPF and other proteins
involved in DNA metabolism (Fekairi et al., 2009; Kim et al.,
2013; Mun˜oz et al., 2009; Svendsen et al., 2009). However,
because the action of these proteins may lead to the formation
of SCE and therefore result in loss of heterozygosity (LOH), their
action is kept under tight control both under physiological condi-
tions and following DNA damage (Dehe et al., 2013; Gallo-
Ferna´ndez et al., 2012; Matos et al., 2011, 2013; Saugar et al.,
2013; Szakal and Branzei, 2013).
Processing of collapsed replication forks by MUS81-EME1 is
essential to the maintenance of genomic integrity (Beck et al.,
2012; Fugger et al., 2013; Hanada et al., 2007). In addition,
absence of MUS81-EME1 may result in failure to remove ultra-
fine DNA bridges (UFBs) and subsequent common fragile site
(CFS)-associated chromosomal instability (Chan et al., 2009;
Naim et al., 2013; Wechsler et al., 2011; Ying et al., 2013). Simi-
larly, Mus81-Mms4EME1 activation operates as a fail-safe mech-
anism in yeast to repair stalled replication forks that escape other
repair pathways (Dehe et al., 2013; Matos et al., 2013; Saugar
et al., 2013). Importantly, because untimely or persistent endo-
nuclease activation may lead to abnormal processing of replica-
tion forks (Gallo-Ferna´ndez et al., 2012; Matos et al., 2013; Sza-
kal and Branzei, 2013), even in the case of replication stress, full
acquisition of endonuclease activity by Mus81-Mms4EME1
occurs after completion of bulk DNA synthesis (Dehe et al.,
2013; Saugar et al., 2013). Recent work has established that
Mus81-Mms4EME1 activation is mostly confined to the G2/M
transition through Cdc5PLK1 phosphorylation of Mms4EME1 in
budding yeast (Gallo-Ferna´ndez et al., 2012; Matos et al., 2013;
Saugar et al., 2013) or Cdc2CDK1 in fission yeast (Dehe et al.,
2013), a process speculated to be similar to the one observed
in mammalian cells in which activation of MUS81-EME1 requires
phosphorylation of EME1 by PLK1 (Matos et al., 2011).
Here, we addressed both the molecular mechanism underly-
ing Vpr-mediated G2/M arrest and its significance for HIV-1 life
cycle. Using a biochemical approach, we found that the SSE
regulator SLX4com interacts with Vpr. We show that Vpr causes
untimely activation of SLX4-bound MUS81-EME1 through the
recruitment of VPRBP and kinase-active PLK1. Importantly,
silencing of subunits of the SLX4com impedes Vpr-induced
G2/M arrest. Finally, we show that the targeting of active
SLX4com by Vpr to HIV-1 DNA is a viral strategy to avoid innate
immune sensing.
RESULTS
Vpr Interacts with the SSE Regulator Complex SLX4
In order to identify cellular partners involved in Vpr-mediated
G2/M arrest, we established a stable monocytic cell line ex-
pressing FLAG- and HA-tagged Vpr (iF/H-Vpr) under the control
of a tetracycline-inducible promoter (THP-1-iF/H-Vpr). THP-1-iF/
H-Vpr or parental THP-1 cells were grown, induced to express
iF/H-Vpr, and harvested before G2/M arrest (Figures 1A and
S1A available online). Following tandem affinity purification,
immunoprecipitated material was resolved on SDS-PAGE and
silver-stained (Figure 1B), and protein partners were identified
by mass spectrometry (MS). Previously identified Vpr partners
were recovered, including subunits of the VPRBP-DDB1-CUL4
E3-ligase complex and UNG2 (Casey et al., 2010) (Figures 1B
and S1B), validating our experimental approach. Interestingly,
the SSE ERCC1-ERCC4 and MUS81-EME1, together with the
SLX4 scaffold protein, were recovered, as well as the poorly
characterized TSPYL1 and C20orf94 subunits of the SLX4com
(Figures 1B and S1B).
We first confirmed the interaction between iF/H-Vpr and the
identified SLX4com subunits by western blot (WB) (Figure 1C).
Importantly, this interaction is specific to Vpr because immuno-purified HIV-2 viral accessory protein Vpx, which is closely
related to Vpr (Tristem et al., 1992), failed to interact with the
SLX4com (Figure S1B). In addition, GFP-tagged SLX4 (GFP-
SLX4), which is expressed in HeLa cells, colocalized with iF/H-
Vpr (Figure S1C), providing further evidence for a physical inter-
action. Interaction between Vpr and SLX4 was also observed in
the presence of 0.1mg/ml ethidium bromide and 0.1 U/ml DNaseI
(Figure S1D), ruling out the requirement for a DNA intermediate.
Next, in vitro interaction experiments were performed using re-
combinant glutathione S-transferase-tagged Vpr (GST-Vpr)
and 6xHistidine-tagged subunits of the SLX4com (HIS6-
C20orf94, HIS6-MUS81, and HIS6-EME1) or the C-terminal
SLX1 binding domain (SBD) of SLX4 (HIS6-SBD) (Figure S1E).
GST-tagged SLX1 (GST-SLX1) was used as a positive control.
Direct interaction was only observed between HIS6-SBD and
GST-Vpr (Figures 1D and S1F; data not shown). Altogether,
these results demonstrate that Vpr directly interacts with the C
terminus of SLX4.
Because direct interaction between VPRBPandVpr is required
for Vpr-mediated G2/M arrest (Zhao et al., 1994), we asked
whether VPRBP, Vpr, and subunits of the SLX4com assemble
into a single complex. To this aim, glycerol gradient sedimenta-
tion of FLAG-purified iF/H-Vpr was performed, followed by WB
analysis of collected fractions. Figure 1E shows an overlap of pro-
tein distribution along the gradient for all tested subunits. In addi-
tion, reciprocal immunoprecipitations (re-IPs) were performed
(Figure 1F, left) using extracts prepared from cells expressing
both FLAG-tagged SLX4 (FLAG-SLX4) and HA-tagged Vpr under
the control of a tetracycline-inducible promoter (iHA-Vpr). Cell ex-
tracts were first subjected to FLAG-IP followed by Flag-peptide
elution under native conditions. Immunopurified material was
further subjected to HA-IP prior to analysis by WB, showing that
all tested subunits of the SLX4com and VPRBP copurified with
Vpr (Figures 1F and S1G). Taken together, the glycerol gradient
velocity analysis and re-IPs strongly suggest that SLX4com sub-
units, VPRBP, and Vpr assemble in a single complex.
Because previous work did not identify VPRBP as a subunit of
the SLX4com, we further explored this interaction in the pres-
ence and absence of Vpr. To this aim, immunoprecipitation (IP)
of FLAG-tagged VPRBP (FLAG-VPRBP) was performed in the
presence or absence of iHA-Vpr. The levels of SLX4, ERCC4,
andMUS81 associated with VPRBPwere significantly enhanced
in Vpr-expressing cells (Figure 1G). This shows that VPRBP inter-
acts with the SLX4com and that Vpr enhances this interaction.
Vpr Causes Untimely Activation of SLX4-Associated
MUS81-EME1
We next wished to uncover whether Vpr expression would
impact on SLX4com activity. We first performed WB analysis
of whole-cell extracts (WCE) from stable HeLa cells induced to
express iF/H-Vpr (HeLa-iF/H-Vpr) for 0, 2, 4, 8, 16, and 24 hr (Fig-
ure 2A). We observed that the levels of EME1 and MUS81
decreased prior to G2/M arrest (4–8 hr). Conversely, the levels
of PLK1 and of its kinase-active Threonine 592-phosphorylated
form (pPLK1)—known to regulate MUS81-EME1 activity through
EME1 phosphorylation—increased before G2/M arrest. This
raised the hypothesis that Vpr expression may modulate
MUS81-EME1 activity through PLK1 activation prior to cell-cycleCell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc. 135
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Figure 1. HIV Vpr Directly Interacts with the C-Terminal Domain of SLX4 and Recruits VPRBP
(A) Experimental scheme for (B) and (C).
(B) iF/H-Vpr was immunopurified as in (A), separated on SDS-PAGE, and silver stained. Major previously described Vpr partners (black), iF/H-Vpr (green), and
SLX4com subunits (red) are indicated. MW, molecular weight (kDa).
(C) Input and eluates prepared as in (A) were analyzed by WB using indicated antibodies.
(D) In vitro interaction assay using HIS6-tagged SLX1 binding domain of SLX4 (HIS6-SBD), GST-SLX1, GST-Vpr, and GST. GST pulled-down material was
analyzed by WB using anti-His and anti-GST antibodies. Additional bands, degradation products of recombinant proteins.
(E) FLAG-purified iF/H-Vpr was peptide eluted and subjected to glycerol-gradient sedimentation. Collected fractions were analyzed by WB using indicated
antibodies.
(F) FLAG-SLX4was purified from 293T cells in the presence of iHA-Vpr (8 hr induction). Peptide-elutedmaterial was further HA immunopurified. Input material and
eluates were analyzed by WB using indicated antibodies.
(G) FLAG-VPRBPwas immunopurified in the presence or absence of iHA-Vpr (8 hr induction) andwas peptide eluted. Eluates and input material were analyzed by
WB using indicated antibodies.
See also Figure S1.
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Figure 2. HIV Vpr Activates SLX4-Bound MUS81-EME1 through
PLK1 Phosphorylation of EME1
(A) HeLa-iF/H-Vpr were induced to express Vpr for the indicated time prior to
cell-cycle analysis using DAPI nuclear staining (top) and WCE and analysis by
WB using indicated antibodies (bottom). h.p.i., hr postinduction.
(B) FLAG-SLX4 was immunopurified from 293T cells expressing or not ex-
pressingVpr for 4 hr. EluateswereanalyzedbySDS-PAGEorPhos-TagandWB
using indicatedantibodies.Cell-cycledistributionanalyzedas in (A) is indicated.
(C) HeLa-iF/H-Vpr cells were either induced to express Vpr for 8 hr or treated
with 0.5mg/ml Noco or 50 nM CPT prior to whole-cell extraction and IP using
anti-SLX4 or IgG. Immunoprecipitates were analyzed as in (B).
(D) FLAG-SLX4 was immunopurified from 293T cells in the presence or
absence of iHA-Vpr. Cleavage of radiolabeled 30 flap and X26 substrates was
analyzed by autoradiography. Right: WB analysis of samples. Graph shows
mean (± SD) cleavage efficiency in the presence of Vpr relative to in the
absence of Vpr (n = 3).
See also Figure S2.arrest. We therefore investigated the phosphorylation status of
EME1 within the SLX4com. To this aim, FLAG-SLX4 was immu-
nopurified from 293T cells in the absence of Vpr or following 4 hr
of Vpr induction (Figure 2B). Using Phos-tag gels that allow the
separation of phosphorylated forms of a protein, we observed
that the expression of Vpr caused the accumulation of slower
migrating bands (pEME1) associated with SLX4 (Figures 2B
and S2A). Furthermore, expression of Vpr caused an increased
recruitment of both PLK1 and pPLK1 to SLX4 (Figures 2B and
S2A). Nocodazole (Noco) treatment was included as a control
since it was previously shown to induce PLK1-dependent phos-
phorylation of EME1 (Figure S2A). Similarly, IP of FLAG-MUS81
showed that, although Vpr did not affect MUS81-EME1 interac-
tion (Figure S2B, left), Vpr expression enhanced the phosphory-
lation of EME1 within the MUS81-EME1 complex (Figure S2B,
right). Importantly, phosphatase treatment of immunoprecipi-
tates prior to migration on Phos-tag gels lead to disappearance
of slower migrating bands, confirming that those correspond to
phosphorylated forms of EME1 (Figure S2B; data not shown).
Altogether, these data suggest that Vpr induces the recruitment
of PLK1 and its kinase active form to SLX4com, resulting
in increased phosphorylation of EME1. Importantly, although
Vpr-mediated remodeling of the SLX4com can be witnessed
after 4 hr of Vpr induction (Figures 2B, S2A, and S2B), 16 to
24 hr induction of Vpr is required for G2/M arrest (Figure 2A).
This shows that Vpr-mediated remodeling of the SLX4com
precedes G2/M arrest.
It has recently been shown that activation of MUS81-EME1 is
confined to late G2/early mitosis to allow processing of late DNA
joint molecules that would otherwise impede the correct segre-
gation of chromosomes. To establish at which stage of the cell
cycle pPLK1 andMUS81-EME1 associate with SLX4 inmamma-
lian cells, cells were arrested in G1/S, S/G2, and mitosis using
2 mM thymidine (Thym), 50 nM camptothecin (CPT), or
0.5 mg/ml nocodazole, respectively. WB analysis of FLAG-
SLX4 immunopurified in these conditions showed increased
recruitment of pEME1 and PLK1 to SLX4 only upon nocodazole
treatment, indicating that, in mammalian cells, SLX4com assem-
bly and EME1 phosphorylation take place during mitosis (Fig-
ure S2C). To rule out the possibility that Vpr-mediated activation
of the SLX4com is a consequence of G2/M arrest, we performed
a similar experiment, including cells that were harvested 8 hr
after Vpr induction. Vpr induced the recruitment of MUS81 and
pEME1 to the SLX4 platform prior G2/M arrest (Figure 2C).
Consistently, Vpr induced the accumulation of PLK1 inWCE dur-
ing G1/S (Figure S2D). Thus, our data suggest that Vpr induces
untimely activation of the SLX4com.
To confirm this hypothesis, we assessed the endonuclease
activity associated with SLX4 in the presence or absence of Vpr
toward 30 flap and X26 (mobile HJ that includes a 26 bp homolo-
gous core) radiolabelled DNA substrates. Human MUS81-EME1
have been shown to display highest processing activity against
30 flap substrates and low activity against X26, whereas human
SLX4-SLX1 target X26 (Sengerova´ et al., 2011; Svendsen and
Harper, 2010). FLAG-SLX4 was purified following 6 hr of iHA-
Vpr induction, and bead-bound FLAG-SLX4 complexes were
tested in in vitro cleavageassays. FLAG-SLX4purified in thepres-
ence of Vpr displayed increased cleavage ability toward 30 flapCell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc. 137
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Figure 3. VPRBP Is Required for Vpr-
Induced Activation of the SLX4com and
Modulation of MUS81 Levels
(A) Experimental scheme was as in Figure 2E,
except that 293T cells were either transfected with
siSCR or siVPRBP prior to whole-cell extraction.
Mean (±SD) cleavage efficiency relative to lane 2
(n = 3).
(B) HeLa-iF/H-Vpr were transfected with siSCR or
siVPRBP 24 hr before induction of iF/H-Vpr
expression for indicated time. WCE were analyzed
by WB using indicated antibodies.
(C) Myc-Ub was coexpressed with FLAG-MUS81
and iHA-Vpr or iHA-VprQ65R in 293T cells. Vpr
expression was induced for 16 hr, and 50 nM
MG132was added to themedia 2 hr prior to whole-
cell extraction and Myc-IP. Immunoprecipitates
and inputs were analyzed by WB using indicated
antibodies.
(D) HeLa-iF/H-Vpr were treated for 20 hr with 2 mM
thymidine prior to release in complete media. Cell
cycle was analyzed using DAPI nuclear staining
(bottom), and WCE were analyzed by WB using
indicated antibodies. h.p.r., hr postrelease.
See also Figure S3.and X26 as compared to FLAG-SLX4 purified in the absence of
Vpr (Figure 2D compare lanes 2–4 and lanes 6–8). To further
examine the contribution of the MUS81-EME1 module, we per-
formed similar experiments after MUS81 knockdown (Figures
S2E–S2G). We thereby observed that MUS81 silencing resulted
in loss of Vpr-mediated increase of SLX4com activity toward
X26 and 30 flap substrates (Figures S2E and S2F, compare lanes
5–7 to 8–10). This suggests that Vpr-mediated increase of
SLX4com activity mostly results from activation of the MUS81-
EME1 module. Altogether, our data indicate that Vpr expression
causesprecociousactivationofSLX4-associatedMUS81-EME1.
VPRBP Is Required for Vpr-Mediated Activation of the
SLX4 Complex and Modulation of MUS81 Levels
Because VPRBP, Vpr, and SLX4com assemble into a single
complex (Figure 1) and, given that VPRBP is required for Vpr-
mediated G2/M arrest, we explored its role in Vpr-mediated acti-
vation of the SLX4com. In vitro nuclease activity assays were
performed using FLAG-SLX4 immunopurified in the presence
or absence of Vpr in nontargeting (SCR) small interfering RNA
(siRNA) or siVPRBP-treated cells (Figures 3A and S3A). Silencing
of VPRBP abolished the Vpr-dependent enhancement of
SLX4com cleavage activity toward X26 (Figure 3A, compare
lanes 3–4 to 5–6). We next wanted to assess whether VPRBP
is required for PLK1 activation. To this aim, HeLa-iF/H-Vpr cells
were transfected with siVPRBP or siSCR and subsequently138 Cell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc.induced to express Vpr. Levels of PLK1
and pPLK1 were assessed by WB. Fig-
ure 3B shows that silencing of VPRBP
abolished Vpr-dependent accumulation
of PLK1 and pPLK1. This supports the
finding that VPRBP is required for the acti-
vation of SLX4-associatedMUS81-EME1.In agreement with results shown in Figure 2A, Vpr induced a
decrease of MUS81 levels that is abolished upon VPRBP
silencing (Figures 3B and S3B). This raised the hypothesis that
VPRBP may be involved in regulating the levels of MUS81.
Thus, we assessed the ubiquitination of MUS81 in the presence
or absence of Vpr. As a control, the ubiquitination of MUS81 was
also assessed in the presence of a Vpr allele with arginine in
place of glutamine at position 65 that does not interact with
VPRBP (VprQ65R). IP of Myc-Ub-associated MUS81 showed
that the expression of WT Vpr, but not of VprQ65R, caused
increased ubiquitination of MUS81 (Figure 3C, compare lanes
4–3 and lanes 5–4). This shows that interaction of VPRBP with
Vpr is involved in MUS81 ubiquitination.
Finally, to rule out that MUS81 degradation may be a conse-
quence of the G2/M arrest, we first treated cells with nocodazole
for up to 24 hr. WB analysis showed that nocodazole treatment
did not induce a significant modulation of MUS81 levels (Fig-
ure S3C). Next, HeLa cells were blocked in G1 using Thymidine
and induced to express Vpr 8 hr prior to release and harvested
2 hr and 8 hr postrelease. WCE were analyzed by WB. In G1-
arrested cells, Vpr expression induced a decrease of MUS81
levels that persisted in S phase (Figure 3D). Of note, in the
absence of Vpr, the levels of MUS81 do not vary in a cell-cycle-
dependent manner (Figure S3C). This shows that Vpr-mediated
MUS81 decrease did not result fromG2/M arrest. Altogether, our
data indicate that the recruitment of VPRBP to the SLX4com is
A B
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Figure 4. Premature Vpr-Induced MUS81-
EME1 Activation Results in FANCD2 Foci Accu-
mulation and G2/M Arrest
(A–D) HeLa cells were induced to express Vpr (A and
C, right) or not (A and C, left) for 24 hr prior to immu-
nofluorescence analysis using anti-FANCD2 antibody
and DAPI staining. Images show representative cells
entering mitosis (C) or not (A). Total number of
cells with FANCD2 foci (C) and the number of twin foci
per mitotic cell (B) upon Vpr expression were counted
in at least 400 cells per condition. Graphs show
mean ± SD.
(E) iF/H-Vpr, iF/H-VprQ65R, and iF/H-VprR80A were
tandem affinity purified from THP-1 cells (11 hr
induction) and analyzed by WB using indicated
antibodies. Fold G2/M is indicated.
(F) HeLa cells were treated as in Figure 3B, except that
siRNAs against SLX4, SLX1, ERCC4, EME1, and
MUS81 were also used. The cell cycle was analyzed
by Flow cytometry measuring incorporation of EdU
and nuclear content (DAPI). Relative G2/G1 ratio is
plotted. Graph shows mean ± SD (n = 3).
(G) Cell-cycle analysis was performed using DAPI
nuclear staining in MEF and MEFSLX4/-expressing
Vpr or treated with 0.5mg/ml Noco for 24 hr. Graph
shows mean ± SD (n = 3).
See also Figure S4.required for Vpr-mediated activation of the SLX4com and regu-
lation of MUS81 levels.
Premature MUS81-EME1 Activation by Vpr Results
in FANCD2 Foci Accumulation and G2/M Arrest
Vpr-induced premature activation of the SLX4-bound MUS81-
EME1 may lead to faulty cleavage of replication intermediates.
Conversely, decreased levels of MUS81 could prevent the pro-
cessing of crossover intermediates before entry into mitosis.
Deregulation of MUS81-EME1 by Vpr may thus lead to accumu-
lation of damaged DNA and subsequent genomic instability.
Because ongoing replication stress and persistence of unre-
solved replication intermediates can be marked by an accumu-
lation of FANCD2 foci (Naim and Rosselli, 2009), these were
quantified by immunofluorescence staining in HeLa-iF/H-Vpr
24 hr post-Vpr induction. We observed a stark increase of
FANCD2 foci upon expression of Vpr (Figures 4A, S4A, and
S4B). Additionally, the number of FANCD2 twin foci was also
dramatically increased in Vpr-positive cells that undergo chro-
mosome condensation (Figures 4B–4D). These increases were
not observed in cells expressing VprQ65R or VprR80A (alanine
to arginine substitution at position 80), suggesting that theseCell 156, 134–1Vpr mutants fail to modulate MUS81-EME1
activity (Figures 4C and 4D).
Consistently, both VprQ65R and VprR80A
have been documented to fail to induce G2/
M arrest. However, mutation R80A does not
disrupt interaction with VPRBP (Belzile et al.,
2007; DeHart et al., 2007). We thus tested
these Vpr alleles for their ability to interact
with members of the SLX4com. To this aim,
cells expressing F/H-iVpr, F/H-iVprQ65R, orF/H-iVprR80A were harvested prior to G2/M arrest, WCE pre-
pared, and subjected to tandem-affinity purification prior to
analysis by WB (Figures 4E and S4C). Consistent with published
observations, VprQ65R failed to interact with VPRBP. Interest-
ingly, VprQ65R failed to interact with SLX4, MUS81, and PLK1.
In contrast, VprR80A interacted with VPRBP and SLX4 but failed
to recruit both MUS81 and PLK1 (Figures 4E and S4C). Thus,
sole interaction of Vpr with VPRBP and SLX4 is not sufficient
to induce G2/M arrest, and recruitment of PLK1 and MUS81-
EME1 is mandatory for this Vpr-associated activity. Altogether,
these observations suggest that Vpr-induced modulation of
MUS81-EME1 activity may result in replication stress.
To further investigate the contribution of subunits of the
SLX4com to Vpr-induced G2/M arrest, we used siRNAs target-
ing VPRBP, SLX4, SLX1, ERCC4, EME1, and MUS81 (Figures
S4D and S4F) in HeLa-iF/H-Vpr prior to 24 hr Vpr induction.
G2/M arrest (Figures 4F and S4D–S4G) and the percentage of
S phase cells (Figures S4G and S4H) weremeasured. As control,
siSCR did not influence Vpr’s ability to induce G2/M arrest.
Silencing of SLX4, SLX1, EME1, and MUS81, but not ERCC4,
caused a reduction of Vpr-induced G2/M arrest. The require-
ment for SLX1 is congruent with the ability of Vpr to increase45, January 16, 2014 ª2014 Elsevier Inc. 139
processing of X26 substrates. In this assay, silencing of VPRBP
caused a more profound disruption of Vpr-induced G2/M arrest
(Figures 4F and S4G) than silencing of SLX4com subunits, mir-
roring siRNA efficiency. Accordingly, Vpr-induced G2/M arrest
is abolished in mouse embryonic fibroblasts (MEF) knocked
out for SLX4 (MEFSLX4/). Furthermore, when siSLX4-treated
HeLa cells are engineered to express SLX4, Vpr-induced G2/M
arrest is restored (Figure S4H).
Of note, modifications of the distribution of cells in S phase
were observed upon siRNA treatment (Figures S4G–S4I). Noco-
dazole treatment of cells knocked down for VPRBP, SLX4, SLX1,
and EME1 demonstrated that these cells were not blocked at the
G1/S transition (data not shown), ruling out the possibility that
the inability of Vpr to induce G2/M arrest in these cells may be
an indirect consequence of a G1/S block. In contrast, MUS81-
silenced cells were blocked at the G1/S transition, indicating
that MUS81 is required to proceed into the S phase. Altogether,
our data confirm the importance of VPRBP in the regulation of
MUS81-EME1 activity and the requirement for SLX4com activa-
tion for Vpr-induced G2/M arrest.
Vpr Activates the SLX4 Complex to Avoid Triggering
Innate Immunity
SLX4 (FANCP) belongs to the Fanconi Anemia (FA) family of pro-
teins. A hallmark of FA, besides heightened cancer susceptibility
and bone marrow failure, is the abnormal production of inter-
feron (IFN) and proinflammatory cytokines (Fagerlie et al.,
2004). Interestingly, Vpr has been shown to modulate IFN
responses (Doehle et al., 2009; Okumura et al., 2008). In light
of recent findings demonstrating that viral manipulation of nucle-
ases plays a role in the control of innate immune signaling (Yan
et al., 2010), we hypothesized that the SLX4com could be sub-
verted by Vpr to avoid eliciting innate immune responses.
HeLa cells were transfected with siSCR, siMUS81, siVPRBP,
and siSLX4 prior to a single-round infection assay using a vesic-
ular stomatitis virus G protein (VSV-G)-pseudotyped HIV-1
molecular clone harboring a IRES-eGFP sequence as a reporter
(HIV-GFP) and type 1 IFN (IFNa and IFNb) and IFN-stimulated
gene (ISG) MxA mRNA quantification by qPCR (Figures 5A and
S5A). In this experimental setting, the percentage of infected
cells was not significantly modified by siRNA treatment (Fig-
ure S5B). Infection of MUS81, VPRBP, and SLX4 knockdown
cells resulted in induction of IFNa, IFNb mRNA, and type 1 IFN
response as demonstrated by induction of MxA mRNA (Fig-
ure 5A). This indicates that MUS81, SLX4, and VPRBP are
required for HIV-1 escape from innate immune sensing. In addi-
tion, infection with VSV-G-pseudotypedHIVDVpr-GFP (HIV-GFP
with a deletion of the vpr open reading frame) caused up to 3-fold
increase of IFNa, IFNb, and MxA mRNAs as compared to infec-
tion with HIV-GFP (Figure 5B).
Because the SLX4com is recruited to damaged DNA, we
explored whether SLX4com subunits are able to bind HIV-1
reverse transcripts. IP of FLAG-SLX4 from HIV-1-infected cells
and quantification of FLAG-SLX4-bound HIV-1 DNA by qPCR
showed significant binding of HIV-1 DNA (Figure 5C). Of note,
binding of HIV-1 DNAwas also observed in FLAG-MUS81 immu-
noprecipitates (Figure S5C). To confirm that HIV-1 DNA bound to
SLX4 was a product of viral reverse transcription, we performed140 Cell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc.a similar experiment using a reverse transcription inhibitor (AZT).
Upon AZT treatment, the binding of SLX4 to viral DNA was abol-
ished (Figure 5D).
To establish whether Vpr is involved in SLX4 binding to HIV-1
DNA, we analyzed SLX4 binding to viral DNA in the presence and
absence of Vpr. We found that, despite similar levels of input viral
DNA (Figure 5E, left) and similar levels of immunoprecipitated
endogenous SLX4 (Figure S5D), HIV DNA was only recovered
after infection with HIV-GFP (Figure 5E, right). This suggests
that Vpr is required for SLX4 binding to HIV-1 DNA. Based on
the above information, one can hypothesize that Vpr induces
SLX4 to bind and process HIV-1 DNA in order to avoid excess
viral DNA accumulation that would otherwise activate IFN pro-
duction. In support, we observed up to 5-fold accumulation of
viral DNA when SLX4 knocked-down HeLa cells were infected
with HIV-1, as compared to infection of SCR-treated HeLa cells
(Figure 5F). Taken together, our experiments identify the target-
ing of active SLX4 by Vpr to HIV-1 DNA as a viral strategy to avoid
innate immune sensing.
The SLX4 Complex Is a Negative Regulator of
Spontaneous Type 1 IFN Production
We next investigated whether MUS81, VPRBP, and SLX4 may
regulate spontaneous IFN production. To this aim, we measured
IFNa, IFNb, and MxA mRNAs after siRNA-mediated silencing of
these SLX4com subunits. We observed that sole silencing
of these proteins resulted in upregulation of IFNa, IFNb, and
MxA mRNAs (Figure 6A). In addition, FANCP patient cells
(RA3331SLX4/), but not their SLX4 reconstituted counterpart
(RA3331SLX4+/+) (Kim et al., 2011), displayed high levels of IFNa,
IFNb, and MxA mRNAs (Figure 6B). In agreement with activation
of the IFN signaling pathway in RA3331SLX4/ cells, we found
high levels of interferon regulatory factors (IRF) 3 and 7 as
compared toRA3331SLX4+/+ (Figure 6C).Concurrently, these cells
displayed a decreased susceptibility to infection with a VSV-G-
pseudotyped HIV molecular clone harboring a luciferase gene
as a reporter (HIV-LUC; Figure 6D). Similar results were
obtainedusingMEFMUS81/cells (FiguresS6AandS6B). In order
to determine whether spontaneous production of type 1 IFN in
MEFMUS81/maybe responsible for thedecreasedsusceptibility
to HIV-1 infection, we infectedMEFwithHIV-LUC in the presence
of conditioned medium collected from MEF or MEFMUS81/
(Figure S6C). Cells treated with the conditioned medium from
MEFMUS81/ caused a 2.5-fold decrease of the susceptibility of
MEF to HIV-LUC infection. Preincubating conditioned medium
from MEFMUS81/ cells with mouse neutralizing antibody to
IFNb abrogated the antiviral effect (Figure S6D). Taken together,
these experiments indicate that SLX4com subunits are respon-
sible for suppressing spontaneous IFN production.
Finally, to determine whether MUS81 contributes to innate
immune signal transduction pathways involved in production of
proinflammatory cytokines, we silenced MUS81 in HEK293 re-
porter cell lines that express the secreted alkaline phosphatase
(SEAP) or renilla luciferase (LUC) reporter genes under the con-
trol of NF-kB and AP-1 transcription factors, respectively (NF-
kB-SEAP and AP-1-LUC). Measurement of reporter gene
expression showed an accumulation of SEAP, whereas no
change was observed in luciferase activity (Figure S6D). This
AC D E F
B
Figure 5. Vpr-Induced SLX4com Manipulation Is Required for Escape of HIV from Innate Immune Sensing
(A) IFNa, IFNb, and MxA induction were measured by RT-qPCR in HeLa cells transfected with siSCR, siMUS81, siVPRBP, or siSLX4 prior to 48 hr infection with
HIV-GFP (n = 3).
(B) HeLa cells were infected for 48 hr with HIV-GFP (WT) or HIVDVpr-GFP (DVpr). Analysis was performed as in (A) (n = 4).
(C) 293T cells overexpressing FLAG-SLX4 were infected with HIV-GFP and harvested at 3, 6, and 16 hr postinfection prior to FLAG-IP and peptide elution. HIV-1
DNA was quantified in eluates by qPCR.
(D) 293T cells were treated as in (C), except that AZT was added at the time of viral infection and cells were harvested 16 hr postinfection. Eluates were analyzed
as in (C).
(E) Cells were infected with HIV-GFP or HIVDVpr-GFP for 16 hr prior to IP using IgG or SLX4-specific antibody. Immunoprecipitates were analyzed as in (C). The
left panel shows input DNA. Ab, antibody.
(F) HeLa cells treated with siSCR or siSLX4 were infected for 48 hr with HIV-GFP prior to qPCR quantification of HIV-1 DNA.
See also Figure S5.indicates that MUS81 specifically prevents activation of the
NF-kBsignal transduction pathway. Importantly, overexpression
of MUS81 did not affect the expression of reporter genes
(Figures S6E–S6G), suggesting that MUS81 does not act as an
innate immune sensor. Altogether, our data indicate that
SLX4com, through the MUS81-EME1 endonuclease, acts as
negative regulator of spontaneous production of type 1-IFN.
DISCUSSION
The identity of involved cellular factors, the underlying molecular
mechanism, and the functional relevance of Vpr-induced G2/Marrest have been long-standing questions in the HIV field.
Here, we show that Vpr interacts with the SLX4 scaffold protein
and activates the MUS81-EME1 endonuclease module through
recruitment of VPRBP and pPLK1 (Figure 7). In somatic cells,
SSE acts as a last resort to process HJ that escape dissolution
by Bloom-related helicases. However, because the action of
these endonucleases may lead to LOH, resolution of HJ by
SSE is tightly regulated. Temporal regulation of Mus81-
Mms4EME1 activity is achieved through phosphorylation of
Mms4EME1 by Cdc5PLK1 (Gallo-Ferna´ndez et al., 2012; Matos
et al., 2011; Saugar et al., 2013) or Cdc2CDK1 in fission yeast
(Dehe et al., 2013). However, untimely or persistent activationCell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc. 141
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Figure 6. The SLX4 Complex Is a Negative Regulator of Sponta-
neous Type 1 IFN Production
(A) HeLa cells treated with siSCR, siMUS81, siVPRBP, or siSLX4 prior to
analysis as in Figure 5A.
(B) RA3331SLX4/ cells from FANCP patients complemented or not com-
plemented with SLX4 (RA3331SLX4+/+) were analyzed as in Figure 5A (n = 3).
(C) Whole-cell extracts from RA3331SLX4/ and RA3331SLX4+/+ cells were
analyzed by WB using indicated antibodies.
(D) RA3331SLX4/ and RA3331SLX4+/+ cells were infected with HIV-LUC for
24 hr. Graph represents mean (± SD) Luciferase activity (n = 3).
See also Figure S6.
Figure 7. Vpr-Induced Manipulation of the SLX4 Complex
Under physiological conditions, the SLX4com is kept in check during the G1
and S phases of the cell cycle. Expression of Vpr in mammalian cells induces
recruitment of pPLK1 and VPRBP to the SLX4com. Subsequently, EME1 is
phosphorylated, and MUS81 is ubiquitinated. This results in activation of
SLX4-bound MUS81-EME1 molecules and leads to processing of HIV-1 DNA,
which contributes to escape from innate immune sensing. Concurrently,
cleavage of replication forks (RF) by activatedMUS81-EME1 in S phase results
in cell-cycle arrest at the G2/M transition. In addition, a decrease in levels of
MUS81 may result in the inability of cells to resolve UFBs in G2, which may
contribute to G2/M arrest. Nonprocessing of UFBs may lead to genomic
instability. Thick arrows represent the prevalent pathway. Question mark
indicates the process for which the extent of contribution to Vpr-associated
phenotypes is unknown. The red bar represents the G2/M transition.
142 Cell 156, 134–145, January 16, 2014 ª2014 Elsevier Inc.of this endonuclease complex results in replication stress,
including the faulty processing of replication intermediates (Blais
et al., 2004; Matos et al., 2013; Szakal and Branzei, 2013).
Here, we show that, in mammalian cells, increased assembly
of SLX4 with active MUS81-EME1 and kinase-active PLK1
essentially occurs in mitotic cells. Vpr expression induced pre-
mature activation of SLX4-bound MUS81-EME1, suggesting
that Vpr causes replication stress. As a testament to ongoing
replication stress and activation of the Fanconi anemia pathway
(Naim and Rosselli, 2009), we observed an accumulation of
FANCD2 foci in Vpr-expressing cells. This is in agreement with
the view that Vpr causes cell-cycle arrest through an S-phase-
dependent mechanism (Li et al., 2010). Importantly, MUS81-
EME1 have been shown to generate DSB by processing stalled
replication forks after prolonged replication stress (Hanada et al.,
2007) and are required for the processing of UFBs (Naim et al.,
2013; Ying et al., 2013). It is therefore possible to speculate
that Vpr expressionmay lead to abnormal cleavage of replication
intermediates by MUS81-EME1 and subsequent accumulation
of DSB. Importantly, SLX4 has been identified as a potential
ATR substrate (Matsuoka et al., 2007; Mu et al., 2007), and phos-
phorylation of Eme1 requires Rad53ATR activation (Dehe et al.,
2013), a pathway that is activated upon Vpr expression (Roshal
et al., 2003); both replication stress and processing of stalled
replication forks would ultimately trigger this pathway and result
in G2/M arrest (Lobrich and Jeggo, 2007).
An interesting finding from our work is the requirement for
VPRBP for Vpr-induced SLX4com activation. This is in agree-
ment with the consensus that posits that interaction of VPRBP
with Vpr is a prerequisite for G2/M arrest. We show that Vpr
targets MUS81 for ubiquitination by VPRBP, resulting in
decreased levels of MUS81. This may be the explanation for
the intriguing observation that Vpr expression caused an
increase of the number of FANCD2 twin foci in mitotic cells.
This is congruent with the recent reports that proteins of the
SLX4com, in particular the MUS81-EME1 module, are required
to untangle UFBs (Chan et al., 2009; Naim et al., 2013; Wechsler
et al., 2011; Ying et al., 2013). Nonetheless, whether ubiquitina-
tion ofMUS81 is required for SLX4com activation or is involved in
regulating active MUS81 levels remains to be investigated. The
complete sequence of events leading from SLX4com premature
activation to cell-cycle arrest will require further investigations for
which we establish Vpr as a powerful molecular tool.
The biological significance of Vpr-mediated G2/M arrest in the
context of viral infection remained unclear, as the requirement for
Vpr in HIV replication was essentially witnessed in nondividing
cells such as macrophages, but not in cycling cells (Casey
et al., 2010; Malim and Emerman, 2008). Our data—showing
that HIV-1 infection of cells in which SLX4com subunits (SLX4,
VPRBP, and MUS81) were knocked down results in type 1 IFN
production—suggest that HIV-1 manipulates the SLX4com to
avoid triggering innate immune responses. Thus, it is possible
that the biological endpoint of Vpr-mediated recruitment of
SLX4com to viral DNA and activation of associated MUS81-
EME1 is to avoid accumulation of excess viral DNA, thereby pre-
venting its sensing and subsequent type 1 IFN production. In
support and in agreement with previous reports (Doehle et al.,
2009; Okumura et al., 2008), infection of cells using HIV-1DVpr
results in increased IFN production as compared to infection
with HIV-1. Thus, we suggest that, similar to the exonucleases
TREX1 and RNASEH2, the SLX4com helps HIV escape innate
immune sensing by processing viral nucleic acid susceptible of
inducing type 1 IFN (Rice et al., 2009; Yan et al., 2010). As for
TREX1 and RNASEH2, SLX4com subunits do not act as nucleic
acid sensors because their overexpression did not lead to IFN
production.
Our study unveils the implication of the SLX4com in sup-
pressing type 1 IFN production in the absence of viral infection.
Indeed, sole silencing of MUS81, SLX4, and VPRBP caused a
production of type1 IFN, induction of ISG, and activation of the
NF-kB transcription factor involved in proinflammatory cytokine
production, and spontaneous production of type 1 IFN was
observed in RA3331SLX4/ and MEFMUS81/ cells. This opensthe question of the nucleic acid species, which accumulate in
the absence of SLX4com that are detected by nucleic acid
sensors and lead to production of IFN. Aberrant replication
intermediates and/or nucleic acids derived from endogenous
retroelements represent possible candidates (Stetson et al.,
2008; Yang et al., 2007). The identification of the SLX4com as
the target of Vpr that accounts for G2/M cell-cycle arrest opens
perspectives in understanding both the function of this viral
accessory protein and the involvement of the DNA repair ma-
chinery in the complex interaction between viruses and innate
immunity.
EXPERIMENTAL PROCEDURES
For detailed experimental procedures, see Supplemental Information.
Purification of Vpr-Associated Complexes
Vpr-associated protein partners were purified from Dignam nuclear extracts
derived from 1.5 3 1010 THP-1-iF/H-Vpr or parental THP-1 cells treated with
doxycyclin for 11 hr by two-step affinity chromatography according to the
standard method (Nakatani and Ogryzko, 2003). Five percent of Flag and HA
immunoaffinity-purified F/H-Vpr or mock IPs were resolved on SDS-PAGE
and stained with the Silverquest kit (Invitrogen). Remainder eluates were
stained with Coomassie-R250. Individual bands or regions of the gel were
excised and analyzed by MS at the Harvard Medical School Taplin Biological
Mass Spectrometry facility.
In Vitro Cleavage Assay
g32P radiolabeled 30 flap and X26 substrates preparation is described in Con-
stantinou et al. (2002). Approximately 30 ng of immunopurified bead-bound
FLAG-SLX4 or mock immunoprecipitate was incubated for 30 min at 37C
with 1 nM substrate in reaction buffer (20 nM Tris [pH7.5], 50 mM NaCl,
10 mMMgCl2, 1 mM MnCl2, 0.1 mg/ml BSA, and 10 mM b-mercaptoethanol).
The reaction was stopped by the addition of 20 mM EDTA. Proteinase K and
SDS were added to a final concentration of 2 mg/ml and 0.4%, respectively,
for 15 min at 37C. Cleavage efficiency was measured by autoradiography
after separation of samples on Tris Borate Ethylamide 8% acrylamide gels.
Analysis of the IFN Pathway
IFNa, IFNb, and Mxa mRNA were quantified by RT-qPCR using specific
probes. Normalization was performed using GAPDH-specific probes.
Infections were performed with 0.1 mg/ml p24 of HIV/HIVDVpr.
NF-kB and AP-1 activity was measured in reporter HEK293 cells lines using
the SEAP reporter or Renilla luciferase reporter kits from Invitrogen and
Promega, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at http://dx.doi.org/10.
1016/j.cell.2013.12.011.
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